Interferon-free Regimen for Genotype-4 Chronic Hepatitis CInterferon-free Regimen for Genotype-4 Chronic Hepatitis C
An all-oral, interferon-free regimen consisting of ombitasvir, paritaprevir and ritonavir is effective at treating patients with genotype-4 chronic hepatitis C virus (HCV), according to a new report from AbbVie. Reuters Health Information
New treatments for hepatitis C virus (HCV) infection with direct-acting antivirals provide an extraordinary cure rate. A recent Article by Xavier Forns and colleagues1 shows an outstanding 99% sustained virological response among all viral genotypes. Because HCV infection is now a curable disease, attention should be focused towards HCV-related complications and indirect effects. Multiple studies in the past have shown that individuals infected with HCV mount a poor response to vaccination against hepatitis B virus (HBV).
Abstract Background:Direct Acting Agents (DAAs) have high cure rate but still lack the knowledge of their effect on hepatic steatosis in chronic hepatitis C (CHC). Controlled Attenuation Parameter (CAP), evaluated with transient elastography, could help in assessment of steatosis grades. We aim to evaluate the effect of DAAs on BMI and steatosis in CHC using CAP.Patients and methods:This cohort study included 155 CHC Egyptian patients divided into three groups according to the DAAs regimens. All patients were subjected to pre‐treatment and 3‐months post‐treatment evaluation including BMI, laboratory workup and liver ...
These new evidence-based recommendations on sofosbuvir –velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults were published in February 2018.
Conclusion: An enhanced screening policy coupled with broader access to DAAs will diminish the future burden of HCV in the Lebanese population and provide the greatest health benefits among middle-aged and elder adults with net cost savings.
Conclusion: IVDU remains a major public health concern in Lebanon, being one of the most prevalent subpopulations for chronic viral hepatitis namely the HCV. Appropriate screening strategies, targeted educational programs and adequate HBV vaccination are of extreme importance for further viral prevention among this high-risk group.
Conclusion: This is the first real world Lebanese data of HCV treatment with DAAs. The study population was significant for a large number of patients with cirrhotic (50%) and treatment experienced patients (42%). SVR12 was achieved in 93% of patients with no difference between treatment na ïve and experienced patients. SVR12 was lower in patients with cirrhosis compared to patients with lower stage of fibrosis (91.3% vs. 98.7%).
(University of Southern California) Heroin is worse than other drugs because people inject it much sooner, potentially resulting in increased risk of injection-related epidemics such as hepatitis C and HIV, a Keck School of Medicine of USC study shows. As more people use opioids, many switch to heroin because it's more potent and cheaper - a trend that complicates disease prevention as health officials crack down on opioids.
(Wiley) In a large ethnically diverse group of patients seen at a community-based Veterans Affairs practice, cure rates for chronic hepatitis C were lower for African American individuals relative to White individuals, even when patients were receiving optimal therapies. The findings are published in Pharmacology Research&Perspectives.
AbstractPurpose of ReviewIncreasing hepatitis C virus (HCV) cases over the past decade have raised concerns about subsequent increased cases in infants due to mother to child transmission (MTCT). Many are reminded of the early days of HIV and the rationale for using antiretroviral agents during pregnancy.Recent FindingsDirect-acting antivirals (DAAs) that are highly potent, all-oral, short-duration regimens that cure HCV have led many to consider what it would entail to use DAAs for pregnant women. Considering HIV and Hepatitis B virus (HBV) as two infections with MTCT to draw lessons from, DAA use to interrupt HCV MTCT co...
Abstract Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure has been linked to improved patient outcomes. In the era of direct‐acting antivirals (DAAs), HCV cure has become the goal, as defined by sustained virological response 12 weeks (SVR12) after completion of therapy. Historically, African‐Americans have had lower SVR12 rates compared to White people in the interferon era, which had been attributed to the high prevalence of non‐CC interleukin 28B (IL28B) type. Less is known about the association between race/ethnicity and SVR12 in DAA‐treated era. The aim of the study is...